Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
Phase 1
Recruiting
- Conditions
- Leber Hereditary Optic Neuropathy (LHON)
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Neurophth Therapeutics Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05820152
- Locations
- 🇺🇸
University of Colorado- Dept of Ophthalmology, Aurora, Colorado, United States
🇨🇳The First Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
Phase 1
Active, not recruiting
- Conditions
- Leber Hereditary Optic Neuropathy (LHON)
- Interventions
- Drug: NR082 InjectionDevice: Injection needle
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Neurophth Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05293626
- Locations
- 🇺🇸
Stanford Byers Eye Institute, Palo Alto, California, United States
🇺🇸Wills Eye Hospital, Neuro Ophthalmology Department, Philadelphia, Pennsylvania, United States
🇺🇸University of Colorado Health Eye Center, Aurora, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath